NCT04779047 is a Phase 4 clinical trial of Remdesivir in Covid19, sponsored by October 6 University.

Who is sponsoring NCT04779047?

NCT04779047 is sponsored by October 6 University.

What drugs are being tested in NCT04779047?

Interventions in NCT04779047: Remdesivir, Hydroxychloroquine, Tocilizumab, Lopinavir/ Ritonavir, Ivermectin.

What condition does NCT04779047 study?

NCT04779047 studies Covid19, Pneumonia.

Is NCT04779047 still recruiting?

NCT04779047 is currently status unknown. Last updated 17 March 2021.

Last reviewed 2021-03-17 · How we verify

NCT04779047

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.

Status unknown Phase 4 Last updated 17 March 2021

What this trial tests

Phase 4 trial testing Remdesivir in Covid19 in 150 participants. Status unknown.

Timeline

1 October 2020

Primary endpoint
10 March 2021

5 April 2021

Quick facts

Lead sponsor	October 6 University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	1 October 2020
Primary completion	10 March 2021
Estimated completion	5 April 2021
Sites	1 location across Egypt

Drugs / interventions tested

Remdesivir (remdesivir) — full drug profile →
Hydroxychloroquine (HYDROXYCHLOROQUINE) — full drug profile →
Tocilizumab (tocilizumab) — full drug profile →
Lopinavir/ Ritonavir
Ivermectin (ivermectin) — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →
Pneumonia — all drugs for Pneumonia →

Sponsor

October 6 University

Who can join

Adults 18 to 88, any sex, with Covid19 or Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparison outcomes of a large cohort of moderate and severe COVID-19 patients received different Antiviral and Anti Inflammatory Drugs.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.
Zizzo G, Tamburello A, Castelnovo L, Laria A, et al · · 2022 · cited 55× · PMID 35340805 · DOI 10.3389/fimmu.2022.795315
Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions.
Jiang Y, Zhao T, Zhou X, Xiang Y, et al · · 2022 · cited 44× · PMID 35923762 · DOI 10.1002/mco2.154
Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells.
Hafezi B, Chan L, Knapp JP, Karimi N, et al · · 2021 · cited 41× · PMID 34359931 · DOI 10.3390/cells10071761
An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).
Elahi R, Karami P, Heidary AH, Esmaeilzadeh A. · · 2022 · cited 33× · PMID 35074571 · DOI 10.1016/j.intimp.2022.108536
Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients.
Sarhan RM, Harb HS, Abou Warda AE, Salem-Bekhit MM, et al · · 2022 · cited 27× · PMID 34764044 · DOI 10.1016/j.jiph.2021.10.024
The Role of Cyclodextrins in COVID-19 Therapy-A Literature Review.
Almeida B, Domingues C, Mascarenhas-Melo F, Silva I, et al · · 2023 · cited 17× · PMID 36769299 · DOI 10.3390/ijms24032974
Mast cells: Therapeutic targets for COVID-19 and beyond.
Lam HY, Tergaonkar V, Kumar AP, Ahn KS. · · 2021 · cited 17× · PMID 34467628 · DOI 10.1002/iub.2552

Verify or expand the search:

Other trials of Remdesivir

Trials testing the same drug.

NCT06817889 — Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals · Phase 2 · recruiting
NCT05911906 — An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. · Phase 4 · completed
NCT06860282 — A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects · Phase 1 · completed
NCT05502081 — Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hos · Phase 4 · completed
NCT05780541 — PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) · Phase 3 · terminated

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other October 6 University trials

Trials by the same sponsor.

NCT07235072 — Passive Fit and Time Efficiency in All On-X Implants Protocols Using Photogrammetry, Splinted Scan Bodies, and Conventio · NA · not yet recruiting
NCT07403851 — Effect of Scanning Technology on the Accuracy of Digitally Customized Intraradicular Attachments · NA · not yet recruiting
NCT07305792 — High Tone Power Therapy on Lumbosacral Radiculopathy Patients · NA · completed
NCT07132736 — Impact of Underwater Exercise Versus Regular Aerobic Exercise on Quality of Life and Power of Muscle · NA · recruiting
NCT07350655 — Efficacy of Virtual Reality-based Training in Patients With Chronic Non-specific Low Back Pain · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04779047 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by October 6 University
Last refreshed: 17 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04779047.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing